3 results on '"Panini Patankar"'
Number of results to display per page
Search Results
2. List of contributors
- Author
-
Arad Abadi, Sherwin Abdoli, Benjamin Acton, Alexandra M. Adams, Aderinsola A. Aderonmu, Rakesh Ahuja, Saleh Aiyash, Gabriel Akopian, Benjamin G. Allar, Michael F. Amendola, Taylor Anderson, Athena Andreadis, Darwin N. Ang, Ersilia Anghel, Favour Mfonobong Anthony, Precious Idorenyin Anthony, Jordan C. Apfeld, Youssef Aref, Fernando D. Arias, Margaret Arnold, Abbasali Badami, Jeffrey Alexander Bakal, Varun V. Bansal, J. Barney, Jessica Barson, Lauren L. Beck, Andrew R. Bender, Vivek Bhat, Saptarshi Biswas, David Blitzer, Tayt Boeckholt, John S. Bolton, Sourav K. Bose, Gerald M. Bowers, Mary E. Brindle, Matthew A. Brown, F. Charles Brunicardi, Richard A. Burkhart, Jennifer L. Byk, M. Campbell, Danilea M. Carmona Matos, Kenny J. Castro-Ochoa, Juan Cendan, Shane Charles, Angel D. Chavez-Rivera, Hao Wei Chen, Herbert Chen, Kevin Chen, Wendy Chen, Darren C. Cheng, Nicole B. Cherng, Christina Shree Chopra, G. Travis Clifton, Jason Crowner, Houston Curtis, Temilolaoluwa O. Daramola, Aria Darbandi, Serena Dasani, Kaci DeJarnette, Jeremiah Deneve, Karuna Dewan, Marcus Dial, Jody C. DiGiacomo, Andrew L. DiMatteo, Tsering Y. Dirkhipa, James M. Dittman, Ashley C. Dodd, Israel Dowlat, Hans E. Drawbert, Juan Duchesne, Omar Elfanagely, Yousef Elfanagely, Javed Khader Eliyas, Chukwuma N. Eruchalu, James C. Etheridge, Erfan Faridmoayer, Arjumand Faruqi, Jessica Dominique Feliz, Martin D. Fleming, Laura M. Fluke, Jason M. Flynn, Kathryn L. Fowler, Miguel Garcia, Tushar Garg, Patrick C. Gedeon, Ruby Gilmor, Julie Goldman, Christian Gonzalez, Rachael E. Guenter, Brian C. Gulack, Matthew Handmacher, Ivy N. Haskins, Carl Haupt, Kshipra Hemal, Matthew T. Hey, Perez Holguin, Christopher S. Hollenbeak, Andrew Holmes, Hyo Jung Hong, Nicholas Huerta, Mohamad A. Hussain, Yaritza Inostroza-Nieves, Marc J. Kahn, Sunil S. Karhadkar, Mohammed A. Kashem, Qingwen Kawaji, Syed Faraz Kazim, Kathryn C. Kelley, Monty U. Khajanchi, Shaarif Rauf Khan, Quynh Kieu, Charissa Kim, Roger Klein, Suzanne Kool, Jessica S. Kruger, Afif N. Kulaylat, Audrey S. Kulaylat, Elizabeth Laikhter, Samuel Lance, Megan LeBlanc, David Lee, Frank V. Lefevre, Jacob Levy, Deacon J. Lile, Carol A. Lin, Xinyi Luo, David A. Machado-Aranda, Kashif Majeed, Madhu Mamidala, Nizam Mamode, Abhishek Mane, Samuel M. Manstein, Jenna Maroney, Jessica Maxwell, Patrick M. McCarthy, Philip McCarthy, Hector Mejia, Pallavi Menon, Albert Moeller, Dennis Spalla Morris, Haley Nadone, Anil Nanda, Allison Nauta, Matthew Navarro, Daniel W. Nelson, Daniel C. Neubauer, Kaitlin A. Nguyen, Louis L. Nguyen, Katherine Nielson, Austin O. McCrea, Delia S. Ocaña Narváez, Peter Oro, Gezzer Ortega, Adena J. Osband, Ahmad Ozair, Rohan Palanki, Jaime Pardo Palau, Juliet Panichella, Panini Patankar, Aneri Patel, Nirmit Patel, Gehan A. Pendlebury, Christina Poa-Li, Sangeetha Prabhakaran, Hashir Qamar, Ramesh Raghupathi, Faique Rahman, Mohan Ramalingam, Syed S. Razi, Aminah Abdul Razzack, Abdul Razzaq, Amanda J. Reich, Christopher Reid, Clay Resweber, Mark Riddle, Mehida Rojas-Alexandre, Susan Rowell, Vanessa Roxo, Debosree Roy, Jacqueline L. Russell, Mala Sachdev, Ruben D. Salas-Parra, Ali Salim, John H. Sampson, Andrea Valquiria Sanchez, Tiffany R. Sanchez, Jane R. Schubart, C. Schwartz, Alexander Schwartzman, Erin M. Scott, Ali Seifi, Aditya Sekhani, Chan Shen, Eric Shiah, Jeffrey W. Shupp, Meaghan Sievers, Rachel E. Silver, Kirit Singh, Robert D. Sinyard, Kevin L. Smith, Tandis Soltani, Abhinav Arun Sonkar, Dallas J. Soyland, Mackinzie A. Stanley, David E. Stein, Sean C. Stuart, Linh Tran, Andrew Vierra, Vanessa M. Welten, Kate Whelihan, Brandon M. White, Rebecca L. Williams-Karnesky, Emily E. Witt, Heather X. Rhodes, Seiji Yamaguchi, Ravali Yenduri, Andrew Yiu, Benjamin R. Zambetti, Christa Zino, and Haley A. Zlomke
- Published
- 2023
- Full Text
- View/download PDF
3. Emerging pharmacotherapies for COVID-19
- Author
-
Panini Patankar and Rachana Salvi
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Pneumonia, Viral ,Anti-Inflammatory Agents ,Remdesivir ,Disease ,RM1-950 ,Antiviral Agents ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,Antimalarials ,Betacoronavirus ,0302 clinical medicine ,Tocilizumab ,Pandemic ,Drug Discovery ,medicine ,Humans ,Immunologic Factors ,Intensive care medicine ,Pandemics ,ComputingMethodologies_COMPUTERGRAPHICS ,Pharmacology ,Anakinra ,Respiratory distress ,business.industry ,SARS-CoV-2 ,Drug Repositioning ,COVID-19 ,Hydroxychloroquine ,Chloroquine ,General Medicine ,medicine.disease ,COVID-19 Drug Treatment ,Pneumonia ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Therapeutics. Pharmacology ,business ,Cytokine storm ,Coronavirus Infections ,Cytokine Release Syndrome ,medicine.drug - Abstract
Graphical abstract, Highlights • Corona Virus Disease (COVID 19) is caused by novel corona virus (nCoV) and may lead to fatality due to Severe Acute Respiratory Syndrome (SARS) in susceptible individuals. • As it is a rapidly evolving situation, rather than developing new drugs, many drugs have been repurposed and are potentially used either prophylactically or therapeutically throughout the world. • SOLIDARITY trial by WHO promotes clinical trial with respect to four potentially useful repurposed drugs namely Chloroquine and hydroxychloroquine, Remdesivir, Lopinavir and Ritonavir combination with or without interferon β. • The drugs mentioned in SOLIDARITY trial are mainly antivirals also used as anti-HIV drugs except for chloroquine and hydroxychloroquine which are anti-malarial drugs which are believed to act through interfering with glycosylation of receptor. • Convalescent plasma therapy is an evolving therapy based on the principle of passive immunity. • As inflammation and cytokine storm is believed to lead to deterioration in patients of COVID 19, anti-cytokine medications are also under research., Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95000 deaths. Vaccines for this deadly virus are currently under development and many drugs used for other indications have been repurposed and investigated for prophylaxis and treatment of COVID 19. As per SOLIDARITY trial by WHO, some of the most promising candidates include chloroquine phosphate and hydroxychloroquine which are anti-malarial medications, Remdesivir, Lopinavir-Ritonavir combination with or without interferon which are anti-HIV drugs and convalescent plasma therapy. The current evidence of efficacy and ongoing research has been elaborated in the article. Besides, there has been evidence regarding inflammatory pathogenesis of this virus leading to cytokine storm in susceptible individuals. Thus, anti-proinflammatory cytokine drugs like Anakinra and Tocilizumab are undergoing multiple trials and some results are encouraging. Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed.
- Published
- 2020
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.